Chapter 3. Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment

  1. David T. Curiel M.D. and
  2. Joanne T. Douglas Ph.D.
  1. Kathleen F. Pirollo Ph.D.,
  2. Liang Xu M.D., Ph.D. and
  3. Esther H. Chang Ph.D.

Published Online: 31 MAR 2003

DOI: 10.1002/0471234303.ch3

Vector Targeting for Therapeutic Gene Delivery

Vector Targeting for Therapeutic Gene Delivery

How to Cite

Pirollo, K. F., Xu, L. and Chang, E. H. (2002) Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch3

Editor Information

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Author Information

  1. Department of Oncology, Georgetown University Medical Center, Lombardi Cancer Center, Washington, D.C., USA

Publication History

  1. Published Online: 31 MAR 2003
  2. Published Print: 9 AUG 2002

ISBN Information

Print ISBN: 9780471434795

Online ISBN: 9780471234302

SEARCH

Keywords:

  • monoclonal antibody;
  • liposomes;
  • immunoliposomes;
  • scFv;
  • gene therapy;
  • tumor targeting;
  • anti-transferrin receptor;
  • p53

Summary

Within the last decade, we have seen a rapid expansion in the use of monoclonal antibodies as targeting molecules in medicine. However, the disadvantages associated with intact antibodies has limited their therapeutic usefulness. The development of small biologically active antibody fragments, such as the scFv molecules, has provided a way to circumvent some of these problems. This, coupled with the use of liposomes as drug and gene delivery vehicles, has broadened the potential of immunotherapy for cancer.

In this chapter we examine some of the factors influencing, and review some of the latest reports describing, the ability of antibody targeted immunoliposomal complexes to target both primary tumors and metastases as we work toward more effective therapeutic modalities.